Skip to main content
Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc. — Investor Relations & Filings

Ticker · VERA ISIN · US92337R1014 US Professional, scientific and technical activities
Open in API
Filings indexed 418 across all filing types
Latest filing 2021-12-17 Capital/Financing Update
Country US United States of America
Listing US VERA

About Vera Therapeutics, Inc.

https://veratx.com/

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological and rare diseases. The company's mission is to change the standard of care and improve patients' lives. Its lead product candidate is atacicept, a novel biologic molecule being developed for the treatment of IgA nephropathy (IgAN), a progressive autoimmune kidney disease. Vera Therapeutics aims to advance its pipeline of innovative therapies to address significant unmet medical needs within immunology.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about an Asset Purchase Agreement and a Loan and Security Agreement entered into by the company, describing financing and capital structure changes. There are no financial statements or comprehensive financial performance data typical of annual or quarterly reports. The document focuses on material definitive agreements and financing activities, which aligns with Capital/Financing Update filings. It is not a full financial report, earnings release, or management discussion. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-12-17 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 10, 2021, by Vera Therapeutics, Inc. The content focuses on the appointment of a new director, Kimball Hall, to the company's board, including details about her compensation and terms. There is no financial data or report content, but rather an announcement of a change in the company's board of directors. According to the filing definitions, announcements of changes in the company's board or senior management fall under Board/Management Information (MANG). The document length is 4508 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the correct classification is MANG with high confidence.
2021-12-15 English
FORM 4 SUBMISSION
Director's Dealing
2021-12-13 English
FORM 3 SUBMISSION
Director's Dealing
2021-12-13 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and references a press release providing a corporate update for the quarter ended September 30, 2021. The document includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data itself. The length is 3524 characters, which is relatively short and consistent with a current report or announcement rather than a full interim or annual report. The document is primarily an announcement of a press release with financial results, not the full financial report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes current reports like Form 8-K that announce events or press releases without full financial data.
2021-11-10 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.